Remdesivir for Adults With COVID-19

This living systematic review examines evidence from randomized trials about the effectiveness and harms of remdesivir treatments for adults with suspected or confirmed COVID-19.

[1]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[2]  Yawen Jiang,et al.  Effectiveness of remdesivir for the treatment of hospitalized COVID‐19 persons: A network meta‐analysis , 2020, Journal of medical virology.

[3]  T. Kuno,et al.  Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials , 2020, Virus Research.

[4]  S. Misra,et al.  Efficacy of various treatment modalities for nCOV‐2019: A systematic review and meta‐analysis , 2020, European journal of clinical investigation.

[5]  G. Guyatt,et al.  Drug treatments for covid-19: living systematic review and network meta-analysis , 2020, BMJ.

[6]  A. Hadeh,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[7]  L. Tian,et al.  Association Between Bariatric Surgery and All-Cause Mortality , 2021, Annals of Internal Medicine.

[8]  R. Bruno,et al.  Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.

[9]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[10]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[11]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[13]  J. Avorn,et al.  Drug Evaluation during the Covid-19 Pandemic. , 2020, The New England journal of medicine.

[14]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[15]  Michael Proschan,et al.  A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. , 2019, The New England journal of medicine.

[16]  Georgia Salanti,et al.  Living systematic reviews: 3. Statistical methods for updating meta-analyses. , 2017, Journal of clinical epidemiology.

[17]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[18]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .